A retrospective study evaluating treatment patterns and survival outcomes in elderly patients with acute myeloid leukemia treated in the United States with either 7+3 or a hypomethylating agent

Authors:

Abstract
No abstract available
Funding Information
  • Takeda Pharmaceutical Company

This publication has 12 references indexed in Scilit: